Sangamo Therapeutics Tops Q1 EPS by 1c
Sangamo Therapeutics (SGMO) reported Q1 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $28.2 million versus the consensus estimate of...
Neutral
or
Sangamo Therapeutics News & Analysis
-
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.30%
Investing.com – U.S. equities were mixed at the close on Tuesday, as gains in the Technology, Basic Materials and Financials sectors propelled shares higher while losses in the Telecoms, Oil...
-
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.09%
Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Utilities, Telecoms and Consumer Goods sectors propelled shares higher while losses in the Technology,...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.11%
Investing.com – U.S. equities were lower at the close on Thursday, as losses in the Financials, Telecoms and Consumer Services sectors propelled shares lower. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
